Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval

Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval

Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared to the 30 minutes needed to dose the original infused formulation. The FDA approval is based on clinical trial results showing the injectable formulation was comparable to infused Keytruda. The post Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval appeared first on MedCity News.

Merck Wins US Approval of Easier-to-Use Version of Cancer Drug Keytruda

Merck & Co. won US approval for a novel version of its widely used cancer drug Keytruda that’s faster to give, a key component of the marketing strategy for one of the world’s best-selling medicines as it nears patent expiration.

A New Shot for Cancer Is Convenient, but Poised to Keep Prices High

The cancer medication Keytruda is the world’s best-selling drug. But with lower-priced competition set to arrive as soon as 2028, Keytruda’s manufacturer, Merck, is on the brink of losing tens of billions of dollars in sales. To keep Keytruda revenue flowing, Merck followed a well-worn playbook. It developed a new version of the drug, given as a shot under the skin, which the Food and Drug Administration approved on Friday. The company is talkin…

US FDA approves Merck's injectable version of blockbuster cancer therapy Keytruda

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

1-Minute Administration: Merck's KEYTRUDA Set for Game-Changing Subcutaneous Delivery Plus New Cancer Use

KEYTRUDA gains EU CHMP support for 1-minute subcutaneous delivery across all adult indications and new approval for early-stage head & neck cancer treatment. US decision expected Q4 2025.

EMA committee recommends approval for injectable version of Merck’s Keytruda - Regional Media News

(Reuters) – The European Medicines Agency’s committee has recommended approval for a new formulation of Merck’s blockbuster cancer therapy Keytruda that can be administered under the skin, the U.S. drugmaker said on Friday. An approval would allow patients to access a faster alternative to the traditional intravenous method, reducing the time required to receive cancer immunotherapy — a treatment Merck has long relied on to fuel growth. Keytruda…